# EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

> **NCT06531824** · PHASE3 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 11000 (estimated)

## Conditions studied

- Kidney Disease, Chronic

## Interventions

- **DRUG:** BI 690517
- **DRUG:** Placebo matching BI 690517
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT06531824
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 11000 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531824, "EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06531824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*